A new technology may be the next big thing for CRISPR
Table of Contents
On a chilly morning last November, Michael Segel stepped through the glass doors of the Broad Institute in Cambridge, Mass., rode the elevator up to the 10th floor, dropped his jacket and bag at his desk and made a beeline to the tissue culture room. He found his lab mate Blake Lash already there. And Lash had news: Their cells had turned green.
At first, Segel didn’t believe it. “There’s no way this works!” he thought. The Petri dishes must have been contaminated. They tried the experiment again. And the next morning, back in the culture room, when they flipped on a UV light, there again were the cells, glowing a ghostly green.
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Comments are Closed